English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Marbofloxacin is a veterinary fluoroquinolone with high activity against  Pasteurella multocida.  We evaluated it’s in vivo activity against  P. multocida  based on in vivo time-kill data in swine using a tissue-cage model. A series of dosages ranging from 0.15 to 2.5 mg/kg were administered intramuscularly after challenge with  P. multocida  type B, serotype 2.    Results  The ratio of the 24 h area under the concentration-time curve divided by the minimum inhibitory concentration (AUC 24 TCF/MIC) was the best PK/PD index correlated with the in vivo antibacterial effectiveness of marbofloxacin ( R 2 = 0.9279). The AUC 24 TCF/MIC necessary to achieve a 1-log 10  CFU/ml reduction and a 3-log 10  CFU/ml (90% of the maximum response) reduction as calculated by an inhibitory sigmoid E max  model were 13.48 h and 57.70 h, respectively.    Conclusions  Marbofloxacin is adequate for the treatment of swine infected with P.  multocida.  The tissue-cage model played a significant role in achieving these PK/PD results.

bmc veterinary research

Integrated pharmacokinetic–Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets